Er det ikke ca 132 millioner aksjer da?
Selv mener jeg det burde være mulig å sette emisjonen i oktober på tilsvarende kurs som sist, kr 2,-
Så da skulle det bli ca 200 millioner aksjer i det sammenslåtte selskapet., gitt at jeg har tolket mergen riktig.
The Merger and Exchange ratio
The Merger is structured as a statutory merger whereby all assets and liabilities of Oncoinvent will be transferred to a newly incorporated wholly owned subsidiary of BerGenBio against consideration to the shareholders in Oncoinvent by way of newly issued shares in BerGenBio and with BerGenBio as the surviving entity. The exchange ratio in the Merger will be 1:3, meaning that Oncoinvent shareholders will in total receive approximately 117.6 million BerGenBio shares, corresponding to approximately 1.20268049 BerGenBio shares per Oncoinvent share.